Gregory J. German
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory J. German has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Andrew M. Kropinski
Department of Pathobiology, University of Guelph, Ontario, Canada
2 shared publications- Riley D. Alvarez
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
2 shared publications - Alan Richard Davidson
Department of Biochemistry, Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
1 shared publication Alexander Cervantes
Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Baylor College of Medicine, Houston, TX, USA
1 shared publicationAlexander P. Hynes
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
1 shared publicationAmany M. Al-Anany
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
1 shared publication
Latest Publications
- Open Access
- 27 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e284
Efficacy of swish and gargle and other collection methods with the use of Abbott ID NOW in COVID-19 detection
Background: To evaluate the efficacy of the Abbott ID NOW system in detecting COVID-19 using different specimen collection methods, emphasizing diagnostic accuracy and patient comfort. Methods: Three cohorts were analyzed, including two using the nasopharyngeal (NP) swab technique and one utilizing the swish-and-gargle (SG) method. Positive percent agreement (PPA), negative percent agreement (NPA), and cycle threshold (Ct) values were assessed to determine the system’s performance. Results: The PPA for the NP swab cohorts averaged around 70%, while the SG cohort exhibited a higher PPA of 80%. All cohorts maintained high NPAs, close to 100%. The SG method significantly reduced false negatives, especially at lower Ct values, indicative of elevated levels of viral RNA. Additionally, the NP swab method, often uncomfortable, posed challenges in repeated testing scenarios, particularly among healthcare workers. Conclusion: While the Abbott ID NOW system demonstrates reliable COVID-19 detection, the SG method emerges as a superior collection technique to NP swabs, offering enhanced diagnostic accuracy and improved comfort for test takers. This study underscores the importance of selecting appropriate collection methods to ensure accurate and efficient COVID-19 testing.
- 27 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e284
Open AccessEfficacy of swish and gargle and other collection methods with the use of Abbott ID NOW in COVID-19 detection
Background: To evaluate the efficacy of the Abbott ID NOW system in detecting COVID-19 using different specimen collection methods, emphasizing diagnostic accuracy and patient comfort. Methods: Three cohorts were analyzed, including two using the nasopharyngeal (NP) swab technique and one utilizing the swish-and-gargle (SG) method. Positive percent agreement (PPA), negative percent agreement (NPA), and cycle threshold (Ct) values were assessed to determine the system’s performance. Results: The PPA for the NP swab cohorts averaged around 70%, while the SG cohort exhibited a higher PPA of 80%. All cohorts maintained high NPAs, close to 100%. The SG method significantly reduced false negatives, especially at lower Ct values, indicative of elevated levels of viral RNA. Additionally, the NP swab method, often uncomfortable, posed challenges in repeated testing scenarios, particularly among healthcare workers. Conclusion: While the Abbott ID NOW system demonstrates reliable COVID-19 detection, the SG method emerges as a superior collection technique to NP swabs, offering enhanced diagnostic accuracy and improved comfort for test takers. This study underscores the importance of selecting appropriate collection methods to ensure accurate and efficient COVID-19 testing.
- Open Access
- 22 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107627
Phage therapy: An international survey of attitudes and experiences amongst clinicians
- 22 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107627
Open AccessPhage therapy: An international survey of attitudes and experiences amongst clinicians
- Open Access
- 8 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107613
Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection
- 8 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107613
Open AccessResults of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection
- Open Access
- 6 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107614
Cross-border dialogue: An international survey of regulators on phage therapy
- 6 September 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107614
Open AccessCross-border dialogue: An international survey of regulators on phage therapy
- Open Access
- 15 January 2025
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 50, 48-59
Phage therapy to treat unresponsive infections: A primer for the clinical microbiology laboratory staff
- 15 January 2025
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 50, 48-59
Open AccessPhage therapy to treat unresponsive infections: A primer for the clinical microbiology laboratory staff
- Open Access
- 1 September 2024
- Published by SAGE Publications in PHAGE: Therapy, Applications, and Research
- Vol. 5 (3) , 173-183
The TolC and Lipopolysaccharide-Specific Escherichia coli Bacteriophage TLS—the Tlsvirus Archetype Virus
Introduction: TLS is a virulent bacteriophage of Escherichia coli that utilizes TolC and lipopolysaccharide as its cell surface receptors. Methods: The genome was reannotated using the latest online resources and compared to other T1-like phages. Results: The TLS genome consists of 49,902 base pairs, encoding 86 coding sequences that display considerable sequence similarity with the T1 phage genome. It also contains 18 intergenic 21-base long repeats, each of them upstream of a predicted start codon and in the direction of transcription. Data revealed that DNA packaging occurs through the pac site-mediated headful mechanism. Conclusions: Based on sequence analysis of its genome, TLS belongs to the Drexlerviridae family and represents the type member of the Tlsvirus genus.
- 1 September 2024
- Published by SAGE Publications in PHAGE: Therapy, Applications, and Research
- Vol. 5 (3) , 173-183
Open AccessThe TolC and Lipopolysaccharide-Specific Escherichia coli Bacteriophage TLS—the Tlsvirus Archetype Virus
Introduction: TLS is a virulent bacteriophage of Escherichia coli that utilizes TolC and lipopolysaccharide as its cell surface receptors. Methods: The genome was reannotated using the latest online resources and compared to other T1-like phages. Results: The TLS genome consists of 49,902 base pairs, encoding 86 coding sequences that display considerable sequence similarity with the T1 phage genome. It also contains 18 intergenic 21-base long repeats, each of them upstream of a predicted start codon and in the direction of transcription. Data revealed that DNA packaging occurs through the pac site-mediated headful mechanism. Conclusions: Based on sequence analysis of its genome, TLS belongs to the Drexlerviridae family and represents the type member of the Tlsvirus genus.
- 29 November 2023
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 8 (3) , 236-240
Early diagnosis of monomicrobial Clostridioides difficile bacteremia in a patient without colitis
Bacteremia is a rare finding among Clostridioides difficile infections. We describe a case of a 67-year-old man with resected colorectal cancer with colostomy who presented with small bowel obstruction and was admitted for lysis of adhesions. On day 8 of admission, he developed leukocytosis and raised inflammatory markers with isolation of Gram-positive bacilli in several blood cultures, which was presumptively identified through blood culture pelleting and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) as C. difficile. The diagnosis was confirmed with conventional culture and reference lab identification and the patient demonstrated clinical response with parenteral then oral vancomycin that briefly worsened when therapy was switched to parenteral metronidazole and then improved once oral vancomycin was resumed. Our case was notable in that the combination of pelleting and MALDI-TOF offered early diagnosis in this patient whose positive blood cultures were suspicious for contamination and in whom there was an absence of diarrheal illness or features of colitis on abdominal imaging. Early diagnosis is critical for the timely initiation of therapy, implementation of infection prevention and control measures and in selection of appropriate therapy for antimicrobial stewardship.
- 29 November 2023
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 8 (3) , 236-240
Early diagnosis of monomicrobial Clostridioides difficile bacteremia in a patient without colitis
Bacteremia is a rare finding among Clostridioides difficile infections. We describe a case of a 67-year-old man with resected colorectal cancer with colostomy who presented with small bowel obstruction and was admitted for lysis of adhesions. On day 8 of admission, he developed leukocytosis and raised inflammatory markers with isolation of Gram-positive bacilli in several blood cultures, which was presumptively identified through blood culture pelleting and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) as C. difficile. The diagnosis was confirmed with conventional culture and reference lab identification and the patient demonstrated clinical response with parenteral then oral vancomycin that briefly worsened when therapy was switched to parenteral metronidazole and then improved once oral vancomycin was resumed. Our case was notable in that the combination of pelleting and MALDI-TOF offered early diagnosis in this patient whose positive blood cultures were suspicious for contamination and in whom there was an absence of diarrheal illness or features of colitis on abdominal imaging. Early diagnosis is critical for the timely initiation of therapy, implementation of infection prevention and control measures and in selection of appropriate therapy for antimicrobial stewardship.
- Open Access
- 1 September 2023
- Published by SAGE Publications in PHAGE: Therapy, Applications, and Research
- Vol. 4 (3) , 112-127
Phage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review
Urinary tract infections (UTIs) are a problem worldwide, affecting almost half a billion people each year. Increasing antibiotic resistance and limited therapeutic options have led to the exploration of alternative therapies for UTIs, including bacteriophage (phage) therapy. This systematic review aims at evaluating the efficacy of phage therapy in treating UTIs. We employed a comprehensive search strategy for any language, any animal, and any publication date. A total of 55 in vivo and clinical studies were included. Of the studies, 22% were published in a non-English language, 32.7% were before the year 1996, and the rest were after 2005. The results of this review suggest that phage therapy for UTIs can be effective; more than 72% of the included articles reported microbiological and clinical improvements. On the other hand, only 5 randomized controlled trials have been completed, and case reports and case series information were frequently incomplete for analysis. Overall, this comprehensive systematic review identifies preliminary evidence supporting the potential of phage therapy as a safe and viable option for the treatment of UTIs.
- 1 September 2023
- Published by SAGE Publications in PHAGE: Therapy, Applications, and Research
- Vol. 4 (3) , 112-127
Open AccessPhage Therapy in the Management of Urinary Tract Infections: A Comprehensive Systematic Review
Urinary tract infections (UTIs) are a problem worldwide, affecting almost half a billion people each year. Increasing antibiotic resistance and limited therapeutic options have led to the exploration of alternative therapies for UTIs, including bacteriophage (phage) therapy. This systematic review aims at evaluating the efficacy of phage therapy in treating UTIs. We employed a comprehensive search strategy for any language, any animal, and any publication date. A total of 55 in vivo and clinical studies were included. Of the studies, 22% were published in a non-English language, 32.7% were before the year 1996, and the rest were after 2005. The results of this review suggest that phage therapy for UTIs can be effective; more than 72% of the included articles reported microbiological and clinical improvements. On the other hand, only 5 randomized controlled trials have been completed, and case reports and case series information were frequently incomplete for analysis. Overall, this comprehensive systematic review identifies preliminary evidence supporting the potential of phage therapy as a safe and viable option for the treatment of UTIs.
- Open Access
- 23 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
A four specimen-pooling scheme reliably detects SARS-CoV-2 and influenza viruses using the BioFire FilmArray Respiratory Panel 2.1
The COVID-19 pandemic required increased testing capacity, enabling rapid case identification and effective contract tracing to reduce transmission of disease. The BioFire FilmArray is a fully automated nucleic acid amplification test system providing specificity and sensitivity associated with gold standard molecular methods. The FilmArray Respiratory Panel 2.1 targets 22 viral and bacterial pathogens, including SARS-CoV-2 and influenza virus. While each panel provides a robust output of information regarding pathogen detection, the specimen throughput is low. This study evaluates the FilmArray Respiratory Panel 2.1 using 33 pools of contrived nasal samples and 22 pools of clinical nasopharyngeal specimens to determine the feasibility of increasing testing capacity, while maintaining detection of both SARS-CoV-2 and influenza virus. We observed 100% detection and 90% positive agreement for SARS-CoV-2 and 98% detection and 95% positive agreement for influenza viruses with pools of contrived or clinical specimens, respectively. While discordant results were mainly attributed to loss in sensitivity, the sensitivity of the pooling assay was well within accepted limits of detection for a nucleic acid amplification test. Overall, this study provides evidence supporting the use of pooling patient specimens, one in four with the FilmArray Respiratory Panel 2.1 for the detection of SARS-CoV-2 and influenza virus.
- 23 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Open AccessA four specimen-pooling scheme reliably detects SARS-CoV-2 and influenza viruses using the BioFire FilmArray Respiratory Panel 2.1
The COVID-19 pandemic required increased testing capacity, enabling rapid case identification and effective contract tracing to reduce transmission of disease. The BioFire FilmArray is a fully automated nucleic acid amplification test system providing specificity and sensitivity associated with gold standard molecular methods. The FilmArray Respiratory Panel 2.1 targets 22 viral and bacterial pathogens, including SARS-CoV-2 and influenza virus. While each panel provides a robust output of information regarding pathogen detection, the specimen throughput is low. This study evaluates the FilmArray Respiratory Panel 2.1 using 33 pools of contrived nasal samples and 22 pools of clinical nasopharyngeal specimens to determine the feasibility of increasing testing capacity, while maintaining detection of both SARS-CoV-2 and influenza virus. We observed 100% detection and 90% positive agreement for SARS-CoV-2 and 98% detection and 95% positive agreement for influenza viruses with pools of contrived or clinical specimens, respectively. While discordant results were mainly attributed to loss in sensitivity, the sensitivity of the pooling assay was well within accepted limits of detection for a nucleic acid amplification test. Overall, this study provides evidence supporting the use of pooling patient specimens, one in four with the FilmArray Respiratory Panel 2.1 for the detection of SARS-CoV-2 and influenza virus.